Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.

This Phase 3 trial is testing whether a new drug combination (tecotabart vedotin plus tislelizumab) works better than standard chemotherapy for people with advanced stomach cancer that has a specific protein called CLDN18.2. The study plans to enroll 752 participants who have not…

This Phase 3 trial tests an injectable drug called TQC2731 in 660 adults with severe asthma that is not well controlled by high-dose inhalers. Participants will receive either the drug or a placebo every 4 weeks for a year. The goal is to see if the drug reduces asthma attacks an…

This Phase 3 trial tests whether a new combination of drugs—TQB2868 (a dual antibody) plus anlotinib capsules—works better than standard chemotherapy for people with metastatic pancreatic cancer that has spread. About 566 participants will be randomly assigned to receive either t…

This study tests a new drug called TQB2934 for people with systemic light chain amyloidosis, a rare disease where abnormal proteins damage organs. The drug is a bispecific antibody that helps the immune system target and destroy harmful cells. The trial will enroll 70 adults who …

This early-stage study tests a new drug called TQB2922, given as a shot under the skin, in 42 people with advanced non-small cell lung cancer that has not responded to standard treatments. The drug is a bispecific antibody designed to block two cancer-related proteins (EGFR and c…

This phase 3 trial tests an injectable drug called TQC2731 in 246 adults with chronic sinusitis and nasal polyps. The drug targets a protein involved in inflammation. Researchers will measure changes in polyp size and nasal congestion over 24 weeks compared to a placebo.

This study tests an injection called TQH2722 in 300 adults with seasonal allergic rhinitis (hay fever). The goal is to see if it safely eases symptoms like sneezing, stuffy nose, and itchy eyes when added to standard allergy treatments. Participants will receive the injection and…